Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit
Selecta Biosciences, a clinical stage biotechnology company, will provide a corporate update and engage in one-on-one investor meetings at the Jefferies Virtual Gene Therapy/Editing Summit on October 27-28, 2021. The presentation is scheduled for 11:00 a.m. EST on October 27. Selecta utilizes its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, enhancing the efficacy of biologic treatments. The company has several programs aimed at enzyme therapies, gene therapies, and autoimmune diseases. For more information, visit selectabio.com.
- None.
- None.
WATERTOWN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Gene Therapy/Editing Summit to be held October 27-28, 2021.
Details on the conference can be found below.
Jefferies Virtual Gene Therapy/Editing Summit
Format: Presentation and one-on-one investor meetings
Date: Wednesday October 27, 2021
Presentation Time: 11:00 a.m. EST
Webcast: Click Here
An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
What is the date of the Jefferies Virtual Gene Therapy/Editing Summit for Selecta Biosciences (SELB)?
What time will Selecta Biosciences (SELB) present at the conference?
Where can I find the webcast for Selecta Biosciences' presentation at the Jefferies Summit?
What platform does Selecta Biosciences (SELB) use for developing therapies?
What types of diseases is Selecta Biosciences (SELB) focusing on with its pipeline?
